Skip to content

US · SKIN · MEDICAL - DEVICES

SkinHealth Systems Inc. (SKIN) intrinsic value and stock valuation

$11.77as of 2026-11-21 · Mkt cap 85.67M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

SkinHealth Systems Inc. DCF and intrinsic value

InvestorsCraft values SKIN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SKIN’s statements →

SkinHealth Systems Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Long Beach, CA 90815 skinhealthsystems.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$300.8M+20.4% 5y CAGRd
20182025
Net income
-$-9.52M
20182025
Free cash flow
$37.2M
20182025
Total equity
$61.1M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$300.8M$334.3M$398M$365.9M$260.1M
Operating income-$-20.8M-$-67.77M-$-130.92M-$-25.84M-$-39.93M
Net income-$-9.52M-$-29.1M-$-100.12M$44.2M-$-378.76M
EPSd-$-70.1K-$-204.22K-$-760.33K$297.8K-$-3.71M
Operating cash flow$37.5M$16.1M$21.8M-$-106.6M-$-28.36M
Capital expenditure-$-300K-$-6.79M-$-13.05M-$-17.39M-$-15.62M
Free cash flow$37.2M$9.34M$8.7M-$-123.99M-$-43.98M
Total assets$499.8M$685.7M$929.1M$1B$1.22B
Total debt$378.7M$568.2M$752.3M$751.8M$746.4M
Net debt$146M$198.1M$229.3M$183.6M-$-155.48M
Total equity$61.1M$51.8M$59.4M$167.1M$302.3M
Cash and short-term investments$232.7M$370.1M$523M$568.2M$901.9M
Income statement
20252024202320222021
Revenue$300.8M$334.3M$398M$365.9M$260.1M
Cost of revenue$104.4M$152M$242.9M$117.1M$81.6M
Gross profit$196.4M$182.3M$155.1M$248.8M$178.5M
Research and development expenses$5.63M$6.3M$10.1M$8.44M$8.2M
Selling, general and administrative expenses$211.5M$243.8M$275.9M$266.2M$210.3M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$217.2M$250.1M$286M$274.6M$218.5M
Cost and expenses$321.6M$402.1M$528.9M$391.7M$300M
Interest income$8.95M$16.6M$23.2M$9.18M$40K
Interest expense$19.3M$10.4M$13.7M$13.4M$11.8M
Depreciation and amortization$25.4M$29.5M$34.7M$22.9M$17.9M
Ebitda$38.7M$10.3M-$-53.56M$81.6M-$-350.93M
Operating income-$-20.8M-$-67.77M-$-130.92M-$-25.84M-$-39.93M
Total other income/expenses, net$14.9M$38.2M$29M$71.2M-$-340.71M
Income before tax-$-5.94M-$-29.55M-$-101.89M$45.3M-$-380.64M
Income tax expense$3.58M-$-450K-$-1.77M$1.11M-$-1.88M
Net income-$-9.52M-$-29.1M-$-100.12M$44.2M-$-378.76M
Weighted average shares outstanding$126.4M$123.8M$131.7M$147.6M$102.1M
Weighted average diluted shares outstanding$135.8M$142.5M$131.7M$148.5M$102.1M
Balance sheet
20252024202320222021
Cash and short-term investments$232.7M$370.1M$523M$568.2M$901.9M
Net receivables$23.4M$28.5M$55M$77.8M$51.4M
Inventory$48M$69.1M$91.3M$109.7M$35.3M
Total current assets$309.5M$477.1M$698.3M$783.3M$1B
Property, plant and equipment, net$14.1M$19.6M$26.4M$33.8M$31.2M
Goodwill and intangible assets$162.4M$171M$187.9M$171M$179.7M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$190.3M$208.6M$230.9M$219.8M$217.9M
Total assets$499.8M$685.7M$929.1M$1B$1.22B
Accounts payable$15.6M$21.9M$44.8M$28.5M$29.1M
Short-term debt$129.1M$5.15M$4.6M$4.96M$3.71M
Deferred revenue$0.00$2.38M$450K$0.00$0.00
Total current liabilities$186.3M$68.2M$115M$71.7M$76.4M
Long-term debt$249.7M$563M$747.7M$746.8M$742.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$252.5M$565.7M$754.7M$764.3M$840.1M
Capital lease obligations$9.24M$16M$13.9M$17.7M$16.5M
Total liabilities$438.7M$633.9M$869.7M$836M$916.5M
Common stock$10K$10K$10K$10K$20K
Retained earnings-$-517.5M-$-507.96M-$-478.87M-$-378.75M-$-418.71M
Accumulated other comprehensive income (loss)-$-1.4M-$-6.95M-$-3.04M-$-4.53M-$-1.26M
Total equity$61.1M$51.8M$59.4M$167.1M$302.3M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$378.7M$568.2M$752.3M$751.8M$746.4M
Net debt$146M$198.1M$229.3M$183.6M-$-155.48M
Cash flow statement
20252024202320222021
Net income-$-9.5M-$-29.1M-$-100.12M$44.4M-$-375.11M
Depreciation and amortization$20.8M$33.7M$34.7M$22M$21.1M
Stock-based compensation$14.8M$26.7M$22.5M$28.5M$12.4M
Change in working capital$10.4M-$-27.39M$23.4M-$-140.28M-$-18.66M
Accounts receivable$8.59M$20.8M$12.9M-$-32.02M-$-31.01M
Inventory$15.8M-$-10.5M$19.6M-$-82.1M-$-9.44M
Accounts payable-$-7.2M-$-43.78M$15.8M$1.61M$10.5M
Net cash provided by operating activities$37.5M$16.1M$21.8M-$-106.6M-$-28.36M
Investments in property, plant and equipment-$-5.16M-$-6.79M-$-13.05M-$-17.39M-$-15.62M
Acquisitions, net$0.00$0.00-$-18.46M-$-1.48M-$-22.9M
Net cash used for investing activities-$-5.16M-$-6.79M-$-31.51M-$-18.87M-$-37.73M
Common stock issued-$-1.57M$0.00$0.00$0.00$938.4M
Common stock repurchased$0.00-$-1.96M-$-32.4M-$-160M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-174.9M-$-158.34M-$-37.45M-$-205.24M$959M
Net change in cash-$-137.4M-$-152.96M-$-45.17M-$-333.69M$892.4M
Cash at end of period$232.7M$370.1M$523M$568.2M$901.9M
Operating cash flow$37.5M$16.1M$21.8M-$-106.6M-$-28.36M
Capital expenditure-$-300K-$-6.79M-$-13.05M-$-17.39M-$-15.62M
Free cash flow$37.2M$9.34M$8.7M-$-123.99M-$-43.98M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About SkinHealth Systems Inc.

        SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling and nanoneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive peptide solutions and take home sprays for treating scalp health. In addition, it operates the MyBeautyHealth mobile application for consumers to earn loyalty points and unlock savings, log skin concerns and receive personalized treatment plans, and find and connect with Hydrafacial providers, as well as offers boosters. The company was formerly known as The Beauty Health Company and changed its name to SkinHealth Systems Inc. in April 2026. The company was founded in 1997 and is headquartered in Long Beach, California.

        CEO
        Pedro Malha
        Employees
        613
        Beta
        1.08

        Explore

        Frequently asked questions

        What is the intrinsic value of SkinHealth Systems Inc. (SKIN)?

        SkinHealth Systems Inc. (SKIN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SKIN undervalued?

        SKIN trades at a price of $11.77 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.